UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease

Baldacci, F; Toschi, N; Lista, S; Zetterberg, H; Blennow, K; Kilimann, I; Teipel, S; ... Hampel, H; + view all (2017) Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. Alzheimer's & Dementia , 13 (9) pp. 993-1003. 10.1016/j.jalz.2017.01.021. Green open access

[thumbnail of Baldacci_Two-level_diagnostic_classification.pdf]
Preview
Text
Baldacci_Two-level_diagnostic_classification.pdf - Accepted version

Download (307kB) | Preview

Abstract

INTRODUCTION: We assessed the diagnostic accuracy of cerebrospinal fluid (CSF) YKL-40 in discriminating (1) clinical Alzheimer's disease (AD) from cognitively healthy controls (HCs) and frontotemporal dementia (FTD) (level I) and (2) patients stratified by different pathophysiological profiles from HCs and FTD following a novel unbiased/descriptive categorization based on CSF biomarkers, independent of cognitive impairment severity (level II). METHODS: YKL-40 was compared among HCs (n = 21), mild cognitive impairment (n = 41), AD (n = 35), and FTD (n = 9) (level I) and among HCs (n = 21), AD pathophysiology (tau and amyloid-β) negative (n = 15), tau positive (n = 15), amyloid-β positive (n = 13), AD pathophysiology positive (n = 33), and FTD (n = 9) (level II). RESULTS: Level I: YKL-40 discriminated AD from HC and FTD (area under the receiver operating characteristic curves [AUROCs] = 0.69, 0.71). Level II: YKL-40 discriminated tau-positive individuals and AD pathophysiology-positive individuals from HC, AD pathophysiology-positive patients from FTD (AUROCs = 0.76, 0.72, 0.73). DISCUSSION: YKL-40 demonstrates fair performance in distinguishing tau-positive patients from HCs, suggesting it may aid clinical diagnosis and support a biomarker-guided pathophysiological stratification.

Type: Article
Title: Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.jalz.2017.01.021
Publisher version: https://doi.org/10.1016/j.jalz.2017.01.021
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Alzheimer's disease, Biomarker-based diagnosis, Biomarkers, Cerebrospinal fluid, Clinical diagnosis, Dementia, Diagnostic biomarkers, Frontotemporal dementia, Mild cognitive impairment, Neurodegeneration, Neuroinflammation, YKL-40
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/1550016
Downloads since deposit
122Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item